Minoryx Therapeutics

Showcase Sponsor

Minoryx is a clinical stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program, a differentiated PPAR gamma agonist (MIN-102), is a candidate for X-linked Adrenoleukodystrophy that has successfully completed phase 1 clinical trials and is now in a pivotal phase 2/3 trial. Minoryx harnesses its unique mechanism of action for potential use in X-ALD, a genetic disease characterized by progressive neurological deterioration with no available pharmacological treatment. Minoryx is also working on expanding the use of MIN-102 into other CNS diseases.

website